Hot Samfurin Semaglutide CAS 910463-68-2 Hot

Gabatarwa zuwa Somaglutide

Somaglutide sabon ƙarni ne na GLP-1 (glucagon kamar peptide-1) analog wanda Daminol da NovoNordisk suka haɓaka.Somaglutide wani nau'in sashi ne na dogon lokaci wanda aka haɓaka bisa tushen tsarin Lilalutide, wanda ke da tasiri mai kyau akan jiyya na nau'in ciwon sukari na 2.Novo Nordisk ya kammala karatun PChemicalbookbaseIIa 6 akan allurar Somaglutide, kuma ya ƙaddamar da sabon aikace-aikacen rajista na magani don allurar mako-mako na Somaglutide ga Hukumar Abinci da Magunguna ta Amurka (FDA) a ranar 5 ga Disamba, 2016, da kuma aikace-aikacen ba da izinin talla (MAA) zuwa Turawa Drug AGudanarwa (EMA).A gefe guda, shirye-shiryen baki sau ɗaya na yau da kullun na Somaglutide a halin yanzu yana cikin matakin asibiti na III.

Amfani

Somaglutide wani nau'in sashi ne na dogon lokaci wanda aka haɓaka bisa tushen tsarin liraglutide, wanda ke da mafi kyawun tasiri a cikin kula da nau'in ciwon sukari na 2.

Bincike

Semeglutide sabon analog ne na GLP-1 wanda ake allurar subcutaneously sau ɗaya a mako.Somaglutide analog ne na GLP-1 na dogon lokaci wanda Novo Nordisk ya haɓaka na tsawon lokaci / w allurar subcutaneous.Idan aka kwatanta da liraglutide, Somaglutide yana da sarkar mai mai tsayi da ƙara yawan hydrophobicity.Koyaya, ana gyara Somaglutide tare da gajeriyar sarkar PEG, kuma ana haɓaka hydrophilicity sosai.Bayan gyare-gyaren PEG, ba zai iya haɗawa kawai tare da albumin ba, yana rufe wurin hydrolysis na DPP-4 enzyme, amma kuma yana rage zubar da jini, tsawaita rayuwar rabin rayuwa da kuma cimma tasirin sake zagayowar.Novo Nordisk's Somaglutide ya rataye DPP-4's Sigliptin, da kuma GLP-1's mawallafi, exenatide mai tsawo (ya kamata a tsara shi don yin gasa kai tsaye tare da gaskiyar Lily. Cin zarafi ya dade a kasuwa).A cikin gwajin, babban kashi na Somicalbook ya rage A1C1.6%, kuma matsakaicin asarar nauyi shine 6 kg.An yi amfani da Somaglutide don bincika inganci da amincin 1.0mg Somaglutide idan aka kwatanta da 2.0mg Exenatide sau ɗaya a mako a cikin marasa lafiya 813 masu ciwon sukari na 2.Lokacin gwaji shine makonni 56, kuma marasa lafiya sun sha maganin ciwon sukari guda 1-2 a baki a lokaci guda.A cikin Disamba 2017, FDA a hukumance ta amince da maganin hypoglycemic na mako-mako GLP-1 Somaglutide wanda NovoNordisk ya haɓaka don tallata a ƙarƙashin sunan kasuwanci Ozempic.Dangane da bayanan gwaji na asibiti, Ozempic na iya rage matakin HbA1c idan aka kwatanta da placebo, Januvia na Merck, Bydureon na AstraZeneca da Lantus na Sanofi.Har ila yau, miyagun ƙwayoyi ya nuna ikon taimakawa marasa lafiya su rasa nauyi.